Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Avino Silver & Gold Mines Q4 and Year-end 2025 Earnings Call - Record $92M Revenues, $102M Cash, La Preciosa Moves Into Extraction
Avino closed 2025 with a clean, heavy-hitting quarter. The company reported record annual revenue of $92.2 million, a cash balance of $102 million and roughly $99 million in working capital, while Q4 ...
- Record full-year revenue of $92.2 million for 2025, and record Q4 revenue of over $30 million.
- Cash on hand reached $102 million at year-end, with working capital of about $99 million.
- Q4 marked a return to primary silver, with silver accounting for 54% of consolidated revenues in the quarter.
- +17 more takeaways
The Beauty Health Company Q4 2025 Earnings Call - Margins Stabilize; 2026 Execution Year, Growth Targeted for 2027
New CEO Pedro Malha, five months on the job, laid out a clear pivot. BeautyHealth is moving from a device placement story to a utilization and consumables-first play, leaning on a 36,000+ installed ba...
- New CEO Pedro Malha (five months tenure) is repositioning the company from device placements to device utilization, emphasizing activation of the 36,000+ installed base.
- Q4 2025 revenue was $82.4 million, down 1.3% year-over-year, a notable improvement versus prior double-digit declines earlier in the year.
- Consumables, the recurring revenue engine, grew 1.7% year-over-year to $57.7 million, highlighting resilience in treatment demand.
- +12 more takeaways
Talphera Q4 2025 Earnings Call - Niyad (nafamostat) Poised to Replace Heparin and Simplify CRRT Anticoagulation
Talphera used its analyst event to push the case that Niyad, its formulation of nafamostat, could materially change anticoagulation in continuous renal replacement therapy. The company announced it ha...
- Talphera reported the NEPHRO CRRT study has reached 50% enrollment, which triggered a $4.1 million tranche; earlier closings added proceeds and as of Dec 31 cash and investments were $20.4 million.
- Management expects to complete enrollment later this year and to file a PMA roughly three months after study completion, targeting a second half 2026 submission. The primary endpoint is a 24-hour circuit outcome, allowing a quick data turnaround.
- Investigators say current CRRT anticoagulation practice is inconsistent: many centers use no anticoagulation, some use heparin, others use citrate, and protocols vary widely across hospitals.
- +9 more takeaways
Caledonia Mining Corporation FY2025 Earnings Call - Gold Rally Funds Bilboes Push, $150m Convertible Secured
Caledonia closed 2025 on a strong, price-driven note, with revenue up 46% to $267 million and EBITDA doubling to $125.3 million. Management says the windfall from higher gold prices, paired with disci...
- Revenue rose 46% to $267 million in FY2025, gross profit was $137 million, EBITDA rose 109% to $125.3 million, and profit after tax was $67.5 million.
- Blanket Mine produced 76,000 ounces in 2025, Bilboes oxide produced 1,683 ounces, total group production ~79,000 ounces; sales 77,000 oz from Blanket.
- The financial outperformance was largely driven by a higher gold price; management repeatedly acknowledged results were price-led rather than purely operational.
- +13 more takeaways
BioLineRx Q4 2025 and Full Year 2025 Earnings Call - GLIX1 IND Approved; First-in-Human GBM Trial Launch Imminent
BioLineRx pivoted decisively in 2025, with GLIX1 emerging as the new lead asset. The Hemispherian IND was cleared, orphan designations were secured in the U.S. and EU, and a first-in-human phase I/II-...
- GLIX1 IND approved and cleared for first-in-human trials, with company on track to initiate the phase I/II-A GBM study by the end of the month.
- GLIX1 received orphan drug designation from both the FDA and the European Medicines Agency, which can accelerate review and provide market exclusivity incentives.
- Phase I portion will enroll up to 30 recurrent or progressive GBM and high-grade glioma patients, primary objective is safety and determination of maximum tolerated or recommended dose; data from phase I expected in the first half of next year according to management.
- +14 more takeaways
Gamehaus Q2 FY2026 Earnings Call - Profitability Rebound While Topline Is Tactically Trimmed for Higher-Quality Growth
Gamehaus reported revenue of $26.3 million in Q2 FY2026, a 7.8% year-over-year decline, but delivered a clearproof of its efficiency push: operating margin expanded to 3.3% from 0.8% and net income ro...
- Total revenue for Q2 FY2026 was $26.3 million, down 7.8% year-over-year from $28.5 million.
- Net income rose approximately 151% year-over-year to about $0.9 million.
- Operating income improved to $0.9 million, driving operating margin to 3.3% versus 0.8% a year ago.
- +16 more takeaways
CuriosityStream Q4 2025 Earnings Call - Licensing set to eclipse subscriptions in 2026 as AI deals accelerate
CuriosityStream closed 2025 with clear momentum. Full year revenue rose 40% to $71.7 million, adjusted free cash flow grew 46% to $13.9 million, and Q4 revenue was $19.2 million, up 36% year over year...
- Full year 2025 revenue rose 40% year over year to $71.7 million, with Q4 revenue up 36% to $19.2 million.
- Adjusted free cash flow for 2025 increased 46% to $13.9 million, and Q4 adjusted free cash flow was $4.3 million.
- CuriosityStream reported its fourth sequential quarter of positive adjusted EBITDA, with Q4 adjusted EBITDA of $1.1 million and full-year adjusted EBITDA of $8.2 million.
- +12 more takeaways
Cemig Fourth Quarter 2025 Earnings Call - Record BRL 6.6bn CapEx Funded by Strong EBITDA and Aaa Rating
Cemig closed 2025 with a clear message, cashing in strong regulated cash flow to finance a record investment surge. Recurring EBITDA was BRL 7.3 billion, full EBITDA BRL 8.3 billion, and the company i...
- Recurring EBITDA BRL 7.3 billion in 2025, full EBITDA BRL 8.3 billion including non-recurring items.
- Record investments of BRL 6.6 billion in 2025, concentrated in distribution, generation and transmission.
- Cemig has nearly BRL 10 billion of distribution investments already built but to be recognized in the 2028 tariff review.
- +14 more takeaways
Westwater Resources Q4 2025 Earnings Call - Kellyton 12 Months From Production if Remaining $50M Secured
Westwater says it is a step away from commercial U.S. battery-grade graphite. The company reports $50 million cash on hand, a phase one Kellyton capex target of $245 million that includes an untouched...
- Company filed 2025 Form 10-K and posted press release and investor presentation to its website.
- Management says Kellyton phase one capex remains approximately $245 million, including an untouched $20 million contingency, after optimization efforts.
- Westwater reports approximately $50 million cash on hand at year-end 2025, and states roughly $50 million of additional capital is needed to substantially complete Kellyton phase one.
- +12 more takeaways
Ermenegildo Zegna Group FY 2025 Earnings Call - Resilient DTC lifts margins despite wholesale and Middle East headwinds
Zegna reported FY2025 revenues of EUR 1,917 million, down 1.5% reported but up 1.1% organically, with a 67.5% gross margin and adjusted EBIT of EUR 163 million (EUR 173 million before a EUR 10 million...
- FY2025 headline numbers: revenues EUR 1,917m (-1.5% reported, +1.1% organic), gross margin 67.5%, adjusted EBIT EUR 163m (EUR 173m ex EUR 10m Saks provision), net profit EUR 109.5m (+20%).
- Direct-to-consumer drove margin expansion, DTC now 82% of branded revenues versus 78% a year ago, and was a primary reason gross margin improved by c.90 basis points.
- Saks Global Chapter 11 hit results, with a total EUR 10m provision recorded across the group; management allocates approximately EUR 3m to Zegna, EUR 2m to Thom Browne, and EUR 5m to Tom Ford.
- +14 more takeaways